Business Context and Reporting Period
Mangoceuticals, Inc. (MGRX), an emerging growth company incorporated in Texas, filed this Form 8-K on December 4, 2025. The filing reports the entry into a material definitive agreement involving a new debt instrument.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. The primary financial metric disclosed is a new debt obligation:
- New Debt Principal: $75,000
- Lender: The Tiger Cub Trust (controlled by CEO Jacob D. Cohen)
- Interest Rate: 18% per annum, compounded monthly
- Maturity Date: December 4, 2026
Material Changes
The company has incurred a new direct financial obligation of $75,000. This represents a material change in the company's capital structure and liquidity position relative to the prior period, as no comparable debt transaction was reported in this specific filing.
Terms, Risks, and Contingencies
The Promissory Note contains several critical terms and risks for investors:
- Mandatory Prepayment: The entire outstanding amount, plus accrued interest and a "Make Whole" premium, must be repaid within five business days following the closing of a "Qualified Financing" (defined as a capital-raising transaction other than similar notes).
- Prepayment Penalty: Voluntary prepayment prior to maturity requires a premium equal to the Make Whole Amount minus accrued interest.
- Default Consequences: Upon an event of default (including insolvency or material adverse effects), the principal amount automatically increases to include the Make Whole Amount, and the obligation becomes immediately due and payable without notice.
- Related Party Transaction: The lender is a trust controlled by the company's CEO and Chairman, Jacob D. Cohen.
Investor Verification Checklist
- Verify the company's current cash position to assess the ability to service the 18% interest rate.
- Review the definition of "Qualified Financing" in the full text of Exhibit 10.1 to understand triggers for immediate repayment.
- Assess the impact of the Make Whole premium on potential future fundraising costs.
- Confirm the status of any other outstanding debt or related-party loans not disclosed in this specific filing.